期刊文献+

多功能复合载药脂质体的制备方法及性能

Preparation and property of multi-function composite doxorubicin-loading lposomes
在线阅读 下载PDF
导出
摘要 以天然大豆卵磷脂为主要材料,胆固醇、近红外量子点CdSeTe和超顺磁性Fe_3O_4粒子为附加材料,DO_X为包封的药物,制备了多功能复合载药脂质体。通过正交试验选取影响复合载药脂质体粒径和包封率的5个因素,即磷脂浓度、药脂比、超声时间、水化温度和Fe_3O_4量,每个因素选取4个水平进行优化实验。根据最优条件,采用薄膜分散发制备了多功能复合载药脂质体并对其粒径、磁性和荧光性质进行了测定。结果表明多功能复合载药脂质体粒径大约200nm、近似球形,且具有良好的近红外荧光性能和磁响应性能。 The multi-function composite doxorubicin-loading liposomes were prepared by the main material of nature soya lecithin, the additional material of cholesterol, the Fe3O4 nanoparticles and CdSeTe QDs as well as the drug of DOX. Taking the size and drug entrapment efficiency as index, orthogonal design of five factors four levels was taken to optimize the condition of multi-function composite doxorubicin-loading liposomes. And the five factors were the concentration of liposome, the ratio of drug to lipid, the ultrasound time, the hydration temperature and the quantity of Fe3O4. According to optimality condition, the multi-function Composite Doxorubicin-loading Liposomes were prepared by the thin-film dispersion method. And the size, the magnetism and the fluorescence properties of liposomes were detected. The results showed that the size of the multi-function composite doxorubicin-loading liposomes were 200nm and had good fluorescence and perfect magnetic responsibility.
出处 《化工进展》 EI CAS CSCD 北大核心 2016年第B11期279-282,共4页 Chemical Industry and Engineering Progress
基金 国家自然科学基金项目(2097072)
关键词 近红外CdSeTe 四氧化三铁 盐酸阿霉素 正交试验 包封率 near-infrared CdSeTe Fe3O4 DOX orthogonal test entrapment efficiency
作者简介 第一作者:李珍珍(1987-),女,博士研究生,主要研究方向为功能生物材料、药物载体等。 联系人:赵强,副教授。E-mail:Zhaoqiang@scu.edu.cn。
  • 相关文献

参考文献4

二级参考文献58

  • 1李铁福,邓英杰,王雨青.磁性脂质体的研究进展[J].药学进展,2002,26(1):5-10. 被引量:16
  • 2张东生,唐秋莎,王子妤,樊祥山.纳米As_2O_3磁性脂质体磁感应加热治疗裸鼠人宫颈癌移植瘤[J].中华物理医学与康复杂志,2006,28(2):102-104. 被引量:10
  • 3李曦,方灯明,何敏博,张超灿.磁性脂质体的制备及应用研究进展[J].材料导报,2006,20(9):51-54. 被引量:10
  • 4刘斌.紫杉醇新剂型——紫杉醇脂质体(力扑素)临床应用观察[J].中国医院用药评价与分析,2007,7(1):59-60. 被引量:25
  • 5Zhang J A,Anyarambhatla G,Ma L,et al.Development and characterization of a novel Cremophor EL free liposomebased paclitaxel (LEP-ETU) formulation[J].Eur J Pharm Biopharm,2005,59(1):177-187.
  • 6Powles R,Mawhorter S,Williams T.Liposomal nystatin (Nyotran) vs.amphotericin B (Fungizone) in empiric treatment of presumed fungal infection in neutropenic patients.Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother,1999,39:14.
  • 7Aradigm Corp.Aradigm receives FDA orphan drug designation for liposomal ciprofloxacin for bronchiectasis[EB/OL].(2007-01-16)[2007-12-13].http://www.findarticles.com/p/articles/mi_m0EIN/is_2007_Jan_16/ai_n17116762.
  • 8NeXstar Pharmaceuticals Inc.New phase Ⅱ data on MiKasome accepted for presentation at International Medical Conference[EB/OL].(1999-02-25)[2007-12-13].http://www.allbusiness.com/medicine-health/diseases-disorders-urogenital/6669302-1.html.
  • 9Dragovich T,Mendelson D,Kurtin S,et al.A phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer[J].Cancer Chemother Pharmacol,2006,58(6):759-764.
  • 10Hana Biosciences Inc.Hana Biosciences presents Marqibo data at the 49th annual meeting of the American Society of Hematology[EB/OL].(2007-12-08)[2007-12-13].http://www.primenewswire.com/newsroom/news.html?d=132754.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部